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Using extracts of AtT-20 cell nuclei, protein binding sites on the POMC gene S-flanking region were examined with an exonuclease protection 
approach. One such binding site, located from - 119 to - 106 bp upstream from the mouse POMC gene transcription initiation site, which exhibited 
a close homology to the activator protein-2 (AP-2) site [l]. A double-stranded oligonucleotide containing this site was subsequently used in gel 
shift assays to demonstrate AP-2 consensus equence binding activity in extracts of AtT-20 cell nuclei. Gel shift competition experiments using 
both homologous and heterologous competitor DNA sequences revealed that the AP-2 like factor(s) exhibited specific binding to the mouse AP-2 
consensus equence. Furthermore, AP-2 factor binding was also modulated by a CTF/NFl-like factor. Pretreatment of AtT-20 cell nuclear extracts 
with alkaline phosphatase prior to inclusion in gel shift assays led to a reduction in the intensities of AP-2 factor-specific bands, indicating a potential 
involvement of protein phosphorylation in AP-2 factor binding in AtT-20 cells. 
Activator protein-2; Proopiomelanocortin; AtT-20 cell; DNA binding protein; Transcription factor 
1. INTRODUCTION 
The proopiomelanocortin (POMC) gene has proved 
to be a valuable model of neuropeptide biosynthesis, 
processing and secretion [2,3]. For instance, several 
reports ([4,5] for review, see [2]) have established that 
regulation of POMC biosynthesis occurs primarily at 
the transcriptional level and this phenomenon is 
generally applicable to other neuropeptide gene systems 
[6]. However, transduction mechanisms responsible for 
alterations in POMC gene transcription rates effected 
by external stimuli are not well understood. Since most 
secretagogue-elicited intracellular events can be ascrib- 
ed to activation of second messenger systems and their 
consequent actions on phosphorylation-dephosphory- 
lation cascade, second messenger esponse elements 
may play a key role in activation of gene transcription. 
A number of such elements have been described in 
other neuropeptide gene systems including: a CAMP 
response element (CRE [7,8]); a phorbol ester (TPA) 
response element (TRE [9, lo]) and elements responding 
to both of the aforementioned second messenger 
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systems [1,8]. In addition, POMC gene glucocorticoid 
response elements (GREs) have been characterized 
[ 1 I- 131 and a recent report has localized a putative cor- 
ticotropin releasing factor (CRF) response element on 
the rat POMC promoter [12]. 
In order to localize novel &acting elements in the 
5 ‘-flanking region of the mouse POMC gene, we 
screened approximately 1 kb of this region with an ex- 
onuclease protection procedure, using nuclear extracts 
of mouse corticotrope tumor cells (AtT-20). The loca- 
tions of exonuclease protection sites were then com- 
pared to the published sequence of this region [14] and 
a putative Activator Protein-2 (AP-2 [l]) site was 
selected for characterization. 
2. MATERIALS AND METHODS 
2. I. Cell culture 
Mouse anterior pituitary tumor cells (AtT-20/D16-16) were main- 
tained in culture as previously described [15]. All cell culture media 
were obtained from Flow Laboratories, Inc., McLean, VA. 
2.2. Preparation of nuclear extracts 
Crude nuclear extracts of AtT-20 cells were prepared using a 
modification of the procedure of Dignam et al. [16]. Extracts were 
stored at -70°C dissolved in a minimal volume of buffer C (contain- 
ing 20 mM Hepes, pH 7.9, 25% glycerol, 0.42 M NaCI, 1.5 mM 
MgClz, 0.2 mM EDTA, 0.5 mM PMSF and 0.5 mM DTT). 
2.3. Exonuclease protection assay 
The exonuclease protection assay has been described elsewhere 
[17]. Briefly, a 2 kb fragment of the mouse POMC promoter region 
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Fig. 1. Localization of a putative AP-2 binding site in the 5 ’ flanking 
region of the mouse POMC gene. As described in section 2, 
increasing concentrations of nuclear extracts of AtT-20 cells were 
incubated with a 3’-end labeled PvuII fragment of the mouse POMC 
promoter region (see section 2). This mixture was then digested 
briefly with a 5’-3’ exonuclease (T7 gene 6 exonuclease) and the 
resulting 32P-labeled fragments were separated on polyacrylamide 
gels, dried and autoradiographed. The M, and associated fragment 
length of each of the more prominent bands (arrows) was determined 
by comparison with coelectrophoresed DNA standards. The 
numerical abels indicate the positions of the exonuclease protection 
sites (deduced from the fragment lengths) relative to the transcription 
start site. The putative AP-2 binding site (AP-2 C.S.) selected for 
further study is also indicated in the text figure in section 3. Data 
were taken from one of 3 experiments that produced similar results. 
(kindly provided by Dr Shosaku Numa, Kyoto, Japan) was subcloned 
into pGEM (-3zf-), Promega, Madison, WI. The resulting plasmid 
(pGEMl201-4) was cut with PvuII so that the luc operator (adjacent 
to the multiple cloning site on the vector) was retained on the 3 ‘-end 
of an approximately 1.4 kb fragment (-1000 to +160 bp of the 
POMC gene + about 240 bp of vector). The fragment was 3’-end- 
labeled and incubated with lac repressor-,&galactosidase fusion pro- 
tein and Immunobeads (Bio-Rad, Richmond, CA) precoupled to 
anti-fl-galactosidase to form a precipitable complex. The “P-DNA- 
immunobead complex was then incubated with O-100 yg nuclear ex- 
tract and digested briefly with T7 gene 6 exonuclease. Finally, 32P- 
DNA fragments were separated on 6% polyacrylamide sequencing 
gels and visualized by autoradiography. All of the reagents used in 
the exonuclease protection assay were purchased from Promega with 
the exception of the Immunobeads and the T7 gene 6 exonuclease (US 
Biochemicals, Cleveland, OH). 
2.4. Gel shift assay 
Detection of DNA binding factors in AtT-20 cell nuclear extracts 
was accomplished using a previously described method [181 with 
minor modifications. In each treatment condition, 5 pg of nuclear ex- 
tract was incubated for 15 min at room temperature with a double- 
stranded, 3 ‘-end labeled oligonucleotide (approximately 0.75 ng per 
tube) in a buffer containing 20 mM Tris-HCl (pH 8), 3 mM MgClz, 
50 mM KCl, 0.1 mM DTT, 0.1 mM EDTA, 20 pg of BSA and 5 pg 
of poly[d(I-C)] (Boehringer Mannheim, Indianapolis, IN). Following 
the incubation period, the mixture was subjected to non-denaturing 
polyacrylamide gel electrophoresis n 50 mM Tris-borate/EDTA buf- 
fer at 10°C and subsequent effects on mobility of the DNA fragment 
through the gel were visualized by autoradiography. The labeled pro- 
be contained 4 copies of the sequence: 
5 ’ -AGCCCCCCTCCCGAGG-3 ’ 
3 ’ -TCGGGGGGAGGGCTCC-5 ’ 
which contains the AP-2 consensus equence identified by the ex- 
onuclease protection assay 5 ’ -CCCCCCTCCC-3 ’ . In some ex- 
periments, double stranded competitor DNA was included in various 
concentrations or nuclear extracts were preincubated with alkaline 
phosphatase coupled to agarose beads (Sigma, St. Louis, MO) as 
specified in the figure legends. Competitor DNA sequences were pur- 
chased from Stratagene (La Jolla, CA) and homologous consensus 
sequences (1 x AP-2 and 4 x AP-2) were synthesized in our 
laboratory using an Applied Biosystems Inc. (Foster City, CA) model 
381B oligonucleotide synthesizer. In order to facilitate comparison of 
data across experiments, competitor DNA concentrations were ad- 
justed so that the number of core sequence copies per unit of com- 
petitor DNA was equivalent for all of the competitor DNA species. 
3. RESULTS 
3.1, Exonuclease protection sites 
Incubation of a 32P-labeled DNA fragment contain- 
ing approximately 1 kb of the 5 ’ -flanking region of the 
mouse POMC gene with increasing concentrations of 
nuclear extracts of AtT-20 cell nuclei produced a 
number of T7 gene 6 exonuclease protection sites 
(Fig. 1). In this assay, the location of a particular pro- 
tection site can be approximated from the relative 
molecular mass (MJ of the fragment generated [17]. 
The approximate positions of the sites labeled in Fig. 1 
are depicted in Scheme 1 (filled arrows). In addition, 
the position of the TATAA box and the transcription 
start site (SS) are shown. A few other putative hormone 
and second messenger inducible elements have been 
described [ 1 l- 131, but as yet, none have been precisely 
localized. 
The locations of the exonuclease protection sites 
were compared to the published sequence of the 
5 ‘-flanking region of the murine POMC gene [14] and 
an AP-2 consensus sequence, indicated above, was 
selected for further study. 
3.2. Characterization of the mouse AP-2 site 
Incubation of 32P-labeled 4 x AP-2 probe with 
Mouse POMC gene--S’ flanking region 
Scheme 1 
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Pig. 2. Characterization of an AP-2-like factor in AtT-20 cell nuclei. 
Gel shift experiments were performed using the “P labeled 4 x AP-2 
probe described in section 2. Typically, 0.75 ng of probe was 
incubated for I5 min with 5 pg per assay tube of nuclear extract, 5 pg 
of po$ d&C), 20 pg of BSA and various concentrations of double 
stranded competitor DNA in a final volume of 40~1. Competitor 
DNA concentrations are given in consensus sequence units as 
described in the text. A value of 25 represents 25-fold more consensus 
sequence units than is contributed by the probe. Protein-DNA 
complexes were separated on non-denaturing polyacrylamide gels, 
dried and autoradiographed. Unbound probe can be seen at the very 
bottom of the lanes. Data were taken from a single representative 
experiment. Each treatment condition was included in at least 4 
experiments. 
nuclear extracts of AtT-20 cells resulted in reduced elec- 
trophoretic mobility of the probe and this effect could 
be modified by inclusion of competitor DNA. An ex- 
ample of the results of a typical competition experiment 
appears in Fig, 2. In general, two bands (see lanes 
labeled 0 in Fig. 2), moving at a reduced rate as com- 
pared to the unbound probe. In addition, these two 
bands were sometimes accompanied by a third, slower 
migrating band (data not shown). In competitor ex- 
periments, four previously identified consensus DNA 
sequences were either ineffective (AP-1, AP-3, SPl) or 
partially effective (CTF/NFl) competitors for nuclear 
factors binding to the 4 x AP-2 probe. As shown in the 
figure, both bands were clearly visible in the presence 
of 100 consensus units of AI?-1 or SPi. Addition of 
AP-3 oligonu~leotide to the binding reaction gave 
results identical to those obtained with AP-I or SPl 
(data not shown). However, addition of CTF/NFl con- 
sensus DNA produced a concentration-related iminu- 
tion of band intensity. As shown in the lanes marked ‘1 
x AP-2’ in the figure, shifted bands were essentially 
abolished by addition of a IQO-fold excess of 3 x AP-2 
consensus sequence. Interestingly, a 25-fold excess of 
unlabeled probe (‘4 x AP-2’) totally abolished the 
shifted bands. 
Treatment of AtT-20 cell nuclear extracts for 10 min 
with alkaline phosphatase immobilized on agarose 
beads essentially abolished shifted bands as compared 
to identical extracts given the same incubation without 
- - ++ 
PHOSPHATASE 
S’-REATMENT 
Fig. 3. Effects of alkahne phosphatase treatment on AP-2 factor 
binding activity. Duplicate aliquots of AtT-20 cell nuciear extracts 
were subjected to gel shift analysis as described in section 2, except 
that the electrophoresis buffer was 100 mM TBE. in addition, 
parafiel aliquots of the extract were pretreated with alkaline 
phosphatase prior to gel shift analysis. Data were taken from a single 
representative experiment, (-) = extract preincubated without 
phosphatase; (+) = extract preincubated with phosphatase. 
the inclusion of phosphatase (Fig. 3). Treatment of 
32P-labeled 4 x AP-2 probe with phosphatase without 
the inclusion of nuclear extract had no effect on the 3tP 
content of the probe (data not shown), 
4. DISCUSSION 
In order to characterize POMC gene 5 ‘-flanking se- 
quences that might communicate receptor-mediated 
signals to transcriptional machinery, we attempted to 
localize possible protein binding sites using an ex- 
onuclease protection assay. One such binding site was 
selected for further characterization. This sequence, 
located -119 to -106 of the mouse POMC gene, 
which was used for construction of the gel shift probe, 
is a permutation of the AP-2 consensus equence deriv- 
ed by Imagawa et al. [I]. As indicated in the schematic 
in section 3, several other exonuclease protection sites 
were routinely seen and are currently under in- 
vestigation- 
The results of the gel shift experiments, represented 
by Fig. 2, indicate that an AP-Zlike factor exists in ex- 
tracts of AtT-20 cell nuclei. Incubation of nuclear ex- 
tracts of AtT-20 cells with a “P-labeled oligonucleotide 
composed of 4 copies of the AP-2 sequence led to 
visualization of two bands exhibiting retarded mobility 
in native gels. The reason that two bands were seen is 
unknown but might result from binding of AP-2 factor 
dimers (slower band) vs monomers (faster band) as pro- 
posed by Yamamoto et al. 171 in their work on the 
somatostatin gene CRE. Since a 100-fold excess of 1 x 
AP-2 sequence was required to abolish shifted bands, 
127 
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while addition of even the lowest concentration (a 
25fold excess of consensus units) of cold 4 x AP-2 
totally abolished both band (Fig. 2), cooperative forces 
may be operating between molecules of the AP-Zlike 
factor or between the AP-2-like factor and other com- 
ponents of the nuclear extracts. Examples of coopera- 
tion between proteins binding to DNA are extensive in 
the literature [19]. As expected, consensus binding sites 
for AP-1 [9,10], AP-3 [20] or SPl [22] were ineffective 
competitors for nuclear factor(s) binding to the probe 
at lOO-fold excess concentrations (Fig. 2). In fact, these 
sequences did not abolish binding even when concen- 
trations as high as 200-fold were utilized (data not 
shown). 
However, significant reductions in gel shift band in- 
tensities were seen after the addition of a 50- or 
lOO-fold excess of the CTF/NFl oligonucleotide. These 
results were suprising because the CTF/NFl sequence 
(coding strand = 5 ’ -TGGCTTGAAGCCAA-3 ’ ) has 
practically no similarities to the AP-2 sequence - see 
[21] for a comparison of CTF/NFl consensus se- 
quences. Therefore, it is unlikely that this is the result 
of a direct competition between CTF/NFl and the 4 x 
AP-2 probe for the AP-2-like factor and suggests in- 
stead that a CTF/NFl-like factor may modulate AP-2 
factor binding via protein-protein interactions. 
The rapid increase in POMC gene transcription in- 
itiation seen after treatment of AtT-20 cells with CRF 
or other secretagogues which utilize CAMP as second 
messenger [2,4,5] is independent of ongoing protein 
synthesis ]231 implicating posttranslational 
mechanisms. Similarly, treatment of these cells with 
phorbol esters, which activates protein kinase C (PKC), 
increases POMC mRNA concentrations [24,25]. Since, 
in HeLa cells, AP-2 mediated transcription can be in- 
creased by treatments which increase either cyclic 
AMP-dependent protein kinase (PKA) activity or PKC 
activity [l], the AP-Zlike protein suggested by the pre- 
sent work may perform a similar function in AtT-20 
cells. Thus, activation of either PKA or PKC in AtT-20 
cells would lead to specific phosphorylation events 
crucial to AP-2 binding or to AP-Zdriven modulation 
of POMC gene expression. As shown in Fig. 3. prein- 
cubation of nuclear extracts of AtT-20 cells with 
alkaline phosphatase reduces band intensities in gel 
shift assays, which is consistent with the first criterion 
of the above hypothesis. In other neuropeptide gene 
systems, phosphorylation mechanisms have been im- 
plicated in modulation of transcription. For example, 
Yamamoto et al. [7] have demonstrated that 
phosphorylation of cellular extracts containing CREB, 
a nuclear trans-acting factor implicated in the regula- 
tion of somatostatin gene transcription, dramatically 
increases CAMP responsive element (CRE)-specific 
transcriptional activation. It was suggested that the 
converse (phosphatase treatment) would have a 
negative effect on CREB mediated transcriptional ac- 
128 
tivation because phosphatase treatment led to a func- 
tional alteration in CREB-CRE binding activity [7]. 
However, alterations in binding were not correlated 
with transcriptional effects since phosphorylation of 
extracts containing CREB by addition of PKA did not 
alter CREB-CRE binding [7]. 
Since converging actions of PKA and PKC have been 
demonstrated at several cellular levels [1,15,26], the 
possible role of protein phosphorylation in the activa- 
tion of POMC gene transcription merits further in- 
vestigation. Investigations that are currently in progress 
in our laboratory will determine if the AP-2-like bin- 
ding factor described in the present work is identical to 
the previously described AP-2 [l] or perhaps a func- 
tional analog. 
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